0 112

Cited 1 times in

Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib

DC FieldValueLanguage
dc.contributor.author김도영-
dc.contributor.author김범경-
dc.contributor.author김승업-
dc.contributor.author박미숙-
dc.contributor.author박준용-
dc.contributor.author백송이-
dc.contributor.author안상훈-
dc.contributor.author전미영-
dc.contributor.author한광협-
dc.date.accessioned2018-11-02T16:40:33Z-
dc.date.available2018-11-02T16:40:33Z-
dc.date.issued2018-
dc.identifier.issn1478-3223-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/165011-
dc.description.abstractBACKGROUND & AIMS: The European Association for the Study of the Liver criteria and the modified Response Evaluation Criteria in Solid Tumors are used for assessing the treatment outcomes of hepatocellular carcinoma. We investigated the inter- and intra-observer reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients with advanced hepatocellular carcinoma treated with sorafenib. METHODS: A total of 99 patients with treatment-naive advanced hepatocellular carcinoma receiving sorafenib were included. The κ-values for the inter- and intra-observer agreement of the treatment response were calculated. RESULTS: Inter-observer agreement for baseline tumour number was excellent, as reflected by the high κ-value. The κ-statistics showed "excellent" concordance between the 2 sets of measurements by observer A regarding the overall responses using the European Association for the Study of the Liver criteria (κ = .948, agreement rate = 84.8%) and modified Response Evaluation Criteria in Solid Tumors (κ = .944, agreement rate = 83.8%; all P < .001). In addition, high κ-values indicated concordance between the first sets of measurements by observers A and B (κ = .991 by the European Association for the Study of the Liver criteria and .988 by modified Response Evaluation Criteria in Solid Tumors, all P < .001). When agreements in radiological overall responses between the 2 sets of measurements by observer B and between the second sets of measurements by observers A and B were calculated, similar results regarding high κ-values (>.8) were obtained. CONCLUSIONS: The reproducibility of the European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in assessing treatment outcomes was high in patients with advanced hepatocellular carcinoma treated with sorafenib.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherWiley-Blackwell-
dc.relation.isPartOfLiver International-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleReproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorMi Young Jeon-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorBeom Kyung Kim-
dc.contributor.googleauthorJun Yong Park-
dc.contributor.googleauthorDo Young Kim-
dc.contributor.googleauthorSang Hoon Ahn-
dc.contributor.googleauthorKwang‐Hyub Han-
dc.contributor.googleauthorSong‐Ee Baek-
dc.contributor.googleauthorHye Soo Kim-
dc.contributor.googleauthorSeung Up Kim-
dc.contributor.googleauthorMi Suk Park-
dc.identifier.doi10.1111/liv.13731-
dc.contributor.localIdA00385-
dc.contributor.localIdA00385-
dc.contributor.localIdA00487-
dc.contributor.localIdA00654-
dc.contributor.localIdA01463-
dc.contributor.localIdA01675-
dc.contributor.localIdA01822-
dc.contributor.localIdA02226-
dc.contributor.localIdA05405-
dc.contributor.localIdA04268-
dc.relation.journalcodeJ02171-
dc.identifier.eissn1478-3231-
dc.identifier.pmid29495116-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/abs/10.1111/liv.13731-
dc.subject.keywordmRECIST-
dc.subject.keywordEASL criteria-
dc.subject.keywordreproducibility-
dc.subject.keywordsorafenib-
dc.contributor.alternativeNameKim, Do Young-
dc.contributor.alternativeNameKim, Beom Kyung-
dc.contributor.alternativeNameKim, Seung Up-
dc.contributor.alternativeNamePark, Mi Sook-
dc.contributor.alternativeNamePark, Jun Yong-
dc.contributor.alternativeNameBaek, Song Ee-
dc.contributor.alternativeNameAhn, Sang Hoon-
dc.contributor.alternativeNameJeon, Mi Young-
dc.contributor.alternativeNameHan, Kwang Hyup-
dc.contributor.affiliatedAuthor김도영-
dc.contributor.affiliatedAuthor김범경-
dc.contributor.affiliatedAuthor김승업-
dc.contributor.affiliatedAuthor박미숙-
dc.contributor.affiliatedAuthor박준용-
dc.contributor.affiliatedAuthor백송이-
dc.contributor.affiliatedAuthor안상훈-
dc.contributor.affiliatedAuthor전미영-
dc.contributor.affiliatedAuthor한광협-
dc.citation.volume38-
dc.citation.number9-
dc.citation.startPage1655-
dc.citation.endPage1663-
dc.identifier.bibliographicCitationLiver International, Vol.38(9) : 1655-1663, 2018-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Radiology (영상의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.